This section of the website contains information that should be considered accurate as of the date presented. You acknowledge that this information may change over time and you should not assume that the information is accurate at a later date. Quest Diagnostics is not obligated to update the information contained in this section of the website.
Nov 5, 2014
- Company Expects to Generate 2% to 5% Revenue Growth and Adjusted Diluted EPS Growth of 8% to 10% on Average Over Next Three Years -
Nov 4, 2014
First major service extension to the company's BRCAvantage™ BRCA1 and BRCA2 mutation test menu offers screening for five new non-BRCA genes shown to increase risk of inherited breast cancer